Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer

Model scores of the 29,894 trials active now.

Model score 14% for any early termination, 8% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2013-07-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: and neckhead andcellradiationcancer
  Phrases that lowered it: patientsand safetymgoralday
• Sponsor's past termination rate: 1.4% (lowers risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 75 (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor's past trials: 222 (lowers risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports with a death: 20.6% (lowers risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Drug's FAERS reports marked serious: 92.7% (raises risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design
• Blinding: none (lowers risk) · Design
• Responsible party: sponsor (lowers risk) · Design
• Collaborators: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer NCT00935961 · started 2009 · scored riskier than 31% of active trials completed
• RAD001, Cisplatin and Concurrent Radiation for Locally Advanced, Inoperable Head and Neck Cancer NCT01057277 · started 2009 · scored riskier than 77% of active trials terminated
• RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN NCT01009346 · started 2009 · scored riskier than 98% of active trials terminated
• Phase II Study of RAD001 Head and Neck Cancer NCT01051791 · started 2010 · scored riskier than 99% of active trials terminated
• A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer NCT01283334 · started 2011 · scored riskier than 99% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.